Autopsy report · NCT03811418

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP was not feasible.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: iOMEDICO AG
Sponsor type: Industry
Conditions: Advanced Breast Cancer; HER2-positive Breast Cancer
Interventions: Trastuzumab; Pertuzumab; Vinorelbine; Docetaxel
Participants: 0
Sites: 1
Countries: Germany

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.